March 08, 2012 -- Quotient Clinical, a business unit of Quotient Bioresearch (“Quotient”), will present two significant poster publications at the forthcoming American Society for Clinical Pharmacology and Therapeutics (ASCPT) meeting to be held on March 12th to 17th in Maryland, USA.
Co-authored with scientists from seven leading pharmaceutical companies; AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer and Takeda, the first publication - Applications of exploratory clinical trials in drug development - review of exploratory trials user group meeting- reviews the proceedings of a user group meeting that discussed the impact of ICHM3 exploratory clinical trials guidance on conventional drug development paradigms.
The second publication, co-authored with scientists from GlaxoSmithKline and entitled: A microtracer study of GSK962040, a motilin receptor agonist, to support dosing regimens in the critical care setting, describes the application of Quotient’s ivMicrotracerTM technology to support the development of an IV drug product for GSK962040 (a selective motilin agonist) for use in the critical care setting.
Mark Egerton, Managing Director, Quotient Clinical commented: “These publications demonstrate our commitment to collaborating with our customers on innovative and high-quality clinical research. ICHM3 exploratory studies are being applied increasingly within drug development, with a clear goal of improving the processes by which new medicines are developed.”
Details of the two publications are:
Applications of exploratory clinical trials in drug development - review of exploratory trials user group meeting
Poster Session I (Abstract ID 347; Poster ID 12)
Date: Thursday 15th March 2012, at 8.00am
A microtracer study of GSK962040, a motilin receptor agonist, to support dosing regimens in the critical care setting
Poster Session II (Abstract ID 445; Poster ID 75)
Date: Friday 16th March 2012, at 8.00am
Quotient will be located at exhibition booth #234 at the conference, and senior members of the Quotient team will be attending the meeting. Copies of the posters will be made available at the booth or via download from the Quotient website at http://www.quotientbioresearch.com/publications/posters.
For further information, please contact:
Tel: 0115 948 6900
About Quotient Clinical
Quotient Clinical, a business unit of Quotient Bioresearch, has over 20 years’ experience providing innovative early drug development solutions to pharmaceutical and biotechnology clients worldwide. Our expertise in Exploratory Clinical Pharmacology, Drug Product Optimisation, and 14C Enabled Drug Development, underpinned by our unique Translational Pharmaceutics™ and Synthesis-to-Clinic™ delivery platforms, adds value to client programs.
About Quotient Bioresearch
Quotient Bioresearch is a leading provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide. The company offers a unique range of drug development service through its three business units – Chemistry and Metabolism, Bioanalytical Sciences and Clinical. Quotient has grown rapidly in the past three years through a combination of both acquisition-led and organic growth.
For further information: www.quotientbioresearch.com